The 5th Device Specific Vigilance Guidance was published which provides guidance for manufacturers of Insulin Infusion Pumps and Integrated meter systems. It contains specific scenarios that should be considered when determining if an incident is reportable. The scenarios are divided in the categories:
The TGA announced changes to the ARTG inclusion process for non-measuring, non-sterile Class I medical devices. The changes include new deliverable for the application and a non-mandatory audits of Class I applications where there are concerns that the device does comply with the legal requirements for Class I medical devices.
In 2019 the Chinese National Medical Products Administration (NMPA) published requirements for the implementation of the Unique Device Identification (UDI) for medical devices. At the moment there is still a pilot project running which delayed the implementation time to January 1st, 2021. From 2021, the first batch of high-risk Class 3 medical devices will need to carry an UDI and the manufacturer has to carry out product coding, data upload and maintenance in accordance with the "Medical Device Unique Identification System Rules".
The Russian government passed a resolution which updated the criteria for medical devices that are exempted from registration in Russia. The criteria were harmonized with the Eurasian legislation and includes e.g. custom-made medical devices.
Russian registration certificates for medical devices that were issued before 2013 and have unlimited validity need to be updated until the end of this year. Those certificates were issued under the old medical device regulation system and need an update in accordance a specific administrative replacement procedure.
The FDA published a proposed rule regarding the intended use of medical devices. It contains the amendment of the respective regulations that everyone can comment on until October 23th. The regulations:
Previous efforts trying to amend the existing rules from 2015 to 2017 never became effective due to concerns from the industry and other stakeholders regarding the off-label use. Therefore, we recommend everyone to analyze the impact of the amendment to your products and comment on the rule if any concerns appear. Especially pay attention to any off-label use that could be considered by the FDA to be part of the intended use of the product.
You can download all Regulatory Affairs Updates compiled for you as a PDF under the following link.